Ben Liu is the co-founder and CEO of Formation Bio. He received his DPhil at Oxford as a Rhodes Scholar, leveraging machine-learning, AI, and big-data to develop diagnostics and therapeutics for Parkinson’s and Alzheimer’s disease. During his graduate work, he observed the way clinical trials bottlenecked the development of new treatments for patients, compelling him to start Formation Bio. Before Formation Bio, Ben graduated from Yale where he was awarded the college’s highest honor at graduation and received his MPhil with distinction in Computational Biology from the Department of Applied Mathematics and Theoretical Physics at Cambridge as a Paul Mellon Fellow. Ben also serves as an Advisor to Harvard Business School’s MS/MBA Program in Biotechnology.

Linhao Zhang is the co-founder and Chief Technology Officer at Formation Bio. He oversees our Product, Engineering, and Operations teams, focused on steering company strategy and ensuring operational excellence for all clinical development activities at the company. Before Formation Bio, Linhao worked in Engineering at Oscar Health and Salesforce. Linhao earned his BS in Computer Science at the University of Texas at Austin.

David is the Chief Business Officer of Formation Bio, where he leads business development and strategy around in- and out-licensing activities. Previously, he was a General Partner at Longwood Fund, a leading VC firm, and co-founder and Chief Innovation Officer at PureTech Health, one of the biotech industry’s pioneering hub-and-spoke drug development companies. He’s served as founder and/or CEO of multiple NASDAQ listed companies, including Pyxis Oncology (NASDAQ:PYXS) and Vor Biopharma (NASDAQ: VOR) and several private venture-backed biotechs including Glyph Biosciences (now Seaport Therapeutics), Vedanta Biosciences, Photys Therapeutics, and Be Biopharma. He previously worked in strategy consulting at Boston Consulting Group and Vertex Partners, and in R&D at P&G Pharmaceuticals.

Gavin Corcoran is the Chief Development Officer at Formation Bio. He is a board certified infectious disease physician and leads the development organization that provides the medical and scientific input to all aspects of drug development at Formation Bio, from product licensing to regulatory approval. Prior to joining Formation Bio, he held several senior leadership roles including CMO at Allergan and Stiefel. He attended medical school at the University of the Witwatersrand in South Africa and internal medicine/infectious diseases training at the University of Texas Health Sciences Center in San Antonio, TX where he was on the faculty prior to joining the pharmaceutical industry over 20 years ago.

James Leslie is the Chief Financial Officer at Formation Bio. Prior to joining Formation Bio he spent eleven years as a CFO at PE and VC-backed growth stage companies in the healthcare (Celmatix), insurance (TitleVest) and education (Flatiron School) industries. Prior to becoming a CFO, James was an investment banker in the Restructuring and Reorganization group at Blackstone. James earned his BA from Vassar College and MBA from Columbia Business School.

Melissa Enbar is Formation Bio’s Chief People Officer, leading the People department at Formation Bio. Melissa came to Formation Bio from Birchbox where she spent 8 years designing and building the Global People and Talent function. Prior to that she ran Recruitment at Harvard Business School, supported Consultant Recruitment and Corporate HR at Oliver Wyman - Delta and was an Executive Team Lead in Human Resources at Target. Melissa earned her BA in Psychology from the University of Maryland.